Oncotype DX testing services for breast and colon cancer
Ended Awarded Last action
- Contract number
- HT941025F0041
- Awardee
-
Exact Sciences Corporation UEI NGBXEJX5GLE9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $116,759
Award facts
- Contract value 23% obligated
-
- $116,758.72 Current, with exercised options
- $511,598.40 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Travis AFB, Fairfield, CA, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $65,287 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $51,471 |
About this award
The Defense Health Agency awarded a delivery order valued at $511,598.40 to Exact Sciences Corporation for Oncotype DX testing services for breast and colon cancer, including testing supplies with annual service and maintenance through March 31, 2030. The award was issued on March 27, 2025, with performance to be conducted at Travis Air Force Base in Fairfield, California. This delivery order is structured as a firm fixed-price contract with no set-aside designation and operates under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule, a General Services Administration governmentwide acquisition contract vehicle for specialized medical laboratory services.
Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, is a medical technology company headquartered in Madison, Wisconsin, specializing in advanced diagnostic testing for cancer screening, detection, and treatment planning. The company's primary offering consists of Oncotype DX gene expression profiling assays that analyze mRNA expression in cancer tumor tissue to assess recurrence risk and predict treatment responsiveness. Exact Sciences has established itself as a leading provider of oncology diagnostic services to federal healthcare agencies, holding multiple blanket purchase agreements and indefinite delivery contracts with the Department of Veterans Affairs, Defense Health Agency, Department of the Army Medical Command, and Air Force organizations, with framework agreements ranging from approximately $335,800 to $5,000,000.
Quick answers
Who was awarded contract HT941025F0041?
HT941025F0041 was awarded to Exact Sciences Corporation by Defense Health Agency (Department of Defense) on March 27, 2025.
How much is contract HT941025F0041 worth?
The government has obligated $116,759 on HT941025F0041. Its potential value, with all options, is $511,598.
Is contract HT941025F0041 an order under another contract?
Yes. HT941025F0041 is a delivery order under V797D70053, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract HT941025F0041 competed?
The extent of competition for HT941025F0041 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award